Dr. Christian Callebaut is a Sr. Director in the Virology Department at Gilead and Head for HIV Clinical Virology. He earned his PhD in Virology from the University of Paris, where he completed his doctoral training in the AIDS & Retrovirus Department at the Institut Pasteur Paris. He continued his training as a post-doctoral fellow at Gladstone Institutes of Virology and Immunology. During his tenure at Gilead, Dr. Callebaut has played an integral role in the R&D of several HIV drugs, and contributed to the development, regulatory application, approval and post-approval support of several antiretrovirals, such as TDF, FTC, EVG, COBI, TAF, BIC, including several combinations of these drugs. More recently, he has been the Virology lead for the development of lenacapavir (LEN, GS-6207), a novel HIV capsid inhibitor currently in clinical evaluation.
